References
- WHO. 10 facts on patient safety [updated 2014 June]. Available from http://www.who.int/features/factfiles/patient_safety/en/.
- Pradhan NP, Bhat SM, Ghadage DP. Nosocomial infections in the medical ICU: a retrospective study highlighting their prevalence, microbiological profile and impact on ICU stay and mortality. J Assoc Physicians India. 2014;62:18–21.
- CLSI. Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. Wayne: Clinical and Laboratory Standards Institute; 2013.
- Villar HE, Jugo MB, Visser M, Hidalgo M, Hidalgo G, Maccallini GC. In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum beta-lactamase. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2014;27:51–5.
- Tangden T, Adler M, Cars O, Sandegren L, Lowdin E. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. J Antimicrob Chemother. 2013;68:1319–26.10.1093/jac/dkt044
- WHO. Antimicrobial resistance: global report on surveillance 2014 [updated 2014 April]. Available from http://www.who.int/drugresistance/documents/surveillancereport/en/.
- Evren E, Azap OK, Colakoglu S, Arslan H. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infec Dis. 2013;76:335–8.10.1016/j.diagmicrobio.2013.04.004
- Sho T, Muratani T, Hamasuna R, Yakushiji H, Fujimoto N, Matsumoto T. The mechanism of high-level carbapenem resistance in Klebsiella pneumoniae: underlying Ompk36-deficient strains represent a threat of emerging high-level carbapenem-resistant K. pneumoniae with IMP-1 beta-lactamase production in Japan. Microb Drug Resist. 2013;19:274–81.10.1089/mdr.2012.0248
- Ma L, Lu PL, Siu LK, Hsieh MH. Molecular typing and resistance mechanisms of imipenem-non-susceptible Klebsiella pneumoniae in Taiwan: results from the Taiwan surveillance of antibiotic resistance (TSAR) study, 2002–2009. J Med Microbiol. 2013;62:101–7.10.1099/jmm.0.050492-0
- Dahmen S, Mansour W, Charfi K, Boujaafar N, Arlet G, Bouallegue O. Imipenem resistance in Klebsiella pneumoniae is associated to the combination of plasmid-mediated CMY-4 AmpC beta-lactamase and loss of an outer membrane protein. Microb Drug Resist. 2012;18:479–83.10.1089/mdr.2011.0214
- Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:233–8.10.1093/jac/dkp428
- Freeman R, Moore LS, Charlett A, Donaldson H, Holmes AH. Exploring the epidemiology of carbapenem-resistant gram-negative bacteria in West London and the utility of routinely collected hospital microbiology data. J Antimicrob Chemother. 2015;70:1212–8.
- Van TD, Dinh Q-D, Vu PD, Nguyen TV, Pham CV, Dao TT, et al. Antibiotic susceptibility and molecular epidemiology of Acinetobacter calcoaceticus–baumannii complex strains isolated from a referral hospital in northern Vietnam. J Glob Antimicrob Resist. 2014;2:318–21.10.1016/j.jgar.2014.05.003
- Peng Y, Bi J, Shi J, Li Y, Ye X, Chen X, et al. Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health care–associated infection control in the hospitals of Southern China: a case-control surveillance study. Am J Infect Control. 2014;42:1308–11.10.1016/j.ajic.2014.08.006
- Master RN, Clark RB, Karlowsky JA, Ramirez J, Bordon JM. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. Int J Antimicro Ag. 2011;38:291–5.10.1016/j.ijantimicag.2011.04.022